MDPI Contact

MDPI AG
St. Alban-Anlage 66,
4052 Basel, Switzerland
Support contact
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18

For more contact information, see here.

Advanced Search

You can use * to search for partial matches.

Search Results

2 articles matched your search query. Search Parameters:
Authors = Reiko Inagi

Matches by word:

REIKO (34) , INAGI (3)

View options
order results:
result details:
results per page:
Articles per page View Sort by
Displaying article 1-50 on page 1 of 1.
Export citation of selected articles as:
Open AccessReview Dietary Metabolites and Chronic Kidney Disease
Nutrients 2017, 9(4), 358; doi:10.3390/nu9040358
Received: 23 February 2017 / Revised: 30 March 2017 / Accepted: 31 March 2017 / Published: 4 April 2017
Viewed by 995 | PDF Full-text (1171 KB) | HTML Full-text | XML Full-text
Abstract
Dietary contents and their metabolites are closely related to chronic kidney disease (CKD) progression. Advanced glycated end products (AGEs) are a type of uremic toxin produced by glycation. AGE accumulation is not only the result of elevated glucose levels or reduced renal clearance
[...] Read more.
Dietary contents and their metabolites are closely related to chronic kidney disease (CKD) progression. Advanced glycated end products (AGEs) are a type of uremic toxin produced by glycation. AGE accumulation is not only the result of elevated glucose levels or reduced renal clearance capacity, but it also promotes CKD progression. Indoxyl sulfate, another uremic toxin derived from amino acid metabolism, accumulates as CKD progresses and induces tubulointerstitial fibrosis and glomerular sclerosis. Specific types of amino acids (d-serine) or fatty acids (palmitate) are reported to be closely associated with CKD progression. Promising therapeutic targets associated with nutrition include uremic toxin absorbents and inhibitors of AGEs or the receptor for AGEs (RAGE). Probiotics and prebiotics maintain gut flora balance and also prevent CKD progression by enhancing gut barriers and reducing uremic toxin formation. Nrf2 signaling not only ameliorates oxidative stress but also reduces elevated AGE levels. Bardoxolone methyl, an Nrf2 activator and NF-κB suppressor, has been tested as a therapeutic agent, but the phase 3 clinical trial was terminated owing to the high rate of cardiovascular events. However, a phase 2 trial has been initiated in Japan, and the preliminary analysis reveals promising results without an increase in cardiovascular events. Full article
(This article belongs to the Special Issue Nutrition and Chronic Kidney Disease)
Figures

Figure 1

Open AccessReview Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis
Int. J. Mol. Sci. 2017, 18(1), 174; doi:10.3390/ijms18010174
Received: 9 December 2016 / Revised: 5 January 2017 / Accepted: 10 January 2017 / Published: 17 January 2017
Cited by 2 | Viewed by 491 | PDF Full-text (470 KB) | HTML Full-text | XML Full-text
Abstract
Chronic kidney disease is a major public health problem around the world. Because the kidney plays a role in reducing glycative stress, renal dysfunction results in increased glycative stress. In turn, glycative stress, especially that due to advanced glycated end products (AGEs) and
[...] Read more.
Chronic kidney disease is a major public health problem around the world. Because the kidney plays a role in reducing glycative stress, renal dysfunction results in increased glycative stress. In turn, glycative stress, especially that due to advanced glycated end products (AGEs) and their precursors such as reactive carbonyl compounds, exacerbates chronic kidney disease and is related to premature aging in chronic kidney disease, whether caused by diabetes mellitus or otherwise. Factors which hinder a sufficient reduction in glycative stress include the inhibition of anti-glycation enzymes (e.g., GLO-1), as well as pathogenically activated endoplasmic reticulum (ER) stress and hypoxia in the kidney. Promising strategies aimed at halting the vicious cycle between chronic kidney disease and increases in glycative stress include the suppression of AGE accumulation in the body and the enhancement of GLO-1 to strengthen the host defense machinery against glycative stress. Full article
(This article belongs to the Special Issue Glyoxalase System)
Figures

Figure 1

Years

Subjects

Refine Subjects

Journals

Refine Journals

Article Types

Refine Types

Countries

Refine Countries
Back to Top